ALX Oncology Announces First Patient Dosed in ASPEN-03, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement